News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
712,647 Results
Type
Article (40530)
Company Profile (267)
Press Release (671850)
Multimedia
Podcasts (50)
Webinars (14)
Section
Business (208179)
Career Advice (2078)
Deals (35998)
Drug Delivery (97)
Drug Development (81389)
Employer Resources (173)
FDA (16488)
Job Trends (15208)
News (350795)
Policy (32988)
Tag
Academia (2627)
Accelerated approval (5)
Adcomms (20)
Allergies (87)
Alliances (50908)
ALS (88)
Alzheimer's disease (1388)
Antibody-drug conjugate (ADC) (126)
Approvals (16491)
Artificial intelligence (267)
Autoimmune disease (21)
Automation (16)
Bankruptcy (362)
Best Places to Work (11935)
BIOSECURE Act (20)
Biosimilars (106)
Biotechnology (185)
Bladder cancer (77)
Brain cancer (27)
Breast cancer (283)
Cancer (2267)
Cardiovascular disease (174)
Career advice (1737)
Career pathing (30)
CAR-T (151)
Cell therapy (425)
Cervical cancer (19)
Clinical research (66218)
Collaboration (856)
Compensation (525)
Complete response letters (20)
COVID-19 (2626)
CRISPR (41)
C-suite (244)
Cystic fibrosis (100)
Data (2203)
Decentralized trials (2)
Denatured (19)
Depression (42)
Diabetes (270)
Diagnostics (6560)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (45)
Drug discovery (121)
Drug pricing (100)
Drug shortages (25)
Duchenne muscular dystrophy (93)
Earnings (87590)
Editorial (37)
Employer branding (21)
Employer resources (147)
Events (114796)
Executive appointments (745)
FDA (17758)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (770)
Gene editing (106)
Generative AI (20)
Gene therapy (308)
GLP-1 (716)
Government (4481)
Grass and pollen (4)
Guidances (59)
Healthcare (19325)
Huntington's disease (23)
IgA nephropathy (27)
Immunology and inflammation (116)
Indications (30)
Infectious disease (2771)
Inflammatory bowel disease (137)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (96)
Interviews (325)
IPO (16719)
IRA (40)
Job creations (3692)
Job search strategy (1466)
Kidney cancer (10)
Labor market (38)
Layoffs (467)
Leadership (18)
Legal (7999)
Liver cancer (75)
Lung cancer (321)
Lymphoma (155)
Machine learning (7)
Management (58)
Manufacturing (308)
MASH (66)
Medical device (13885)
Medtech (13890)
Mergers & acquisitions (19833)
Metabolic disorders (685)
Multiple sclerosis (81)
NASH (16)
Neurodegenerative disease (88)
Neuropsychiatric disorders (27)
Neuroscience (1925)
NextGen: Class of 2025 (6761)
Non-profit (4568)
Now hiring (39)
Obesity (364)
Opinion (208)
Ovarian cancer (75)
Pain (87)
Pancreatic cancer (83)
Parkinson's disease (150)
Partnered (21)
Patents (236)
Patient recruitment (110)
Peanut (47)
People (58463)
Pharmaceutical (64)
Pharmacy benefit managers (18)
Phase I (20629)
Phase II (29149)
Phase III (21740)
Pipeline (1189)
Policy (139)
Postmarket research (2572)
Preclinical (8781)
Press Release (65)
Prostate cancer (107)
Psychedelics (30)
Radiopharmaceuticals (250)
Rare diseases (380)
Real estate (6073)
Recruiting (65)
Regulatory (22593)
Reports (46)
Research institute (2391)
Resumes & cover letters (362)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (69)
Series A (134)
Series B (87)
Service/supplier (16)
Sickle cell disease (52)
Special edition (14)
Spinal muscular atrophy (150)
Sponsored (32)
Startups (3642)
State (2)
Stomach cancer (13)
Supply chain (70)
Tariffs (39)
The Weekly (29)
Vaccines (695)
Venture capitalists (42)
Weight loss (236)
Women's health (35)
Worklife (17)
Date
Today (177)
Last 7 days (880)
Last 30 days (2675)
Last 365 days (33335)
2025 (10793)
2024 (35780)
2023 (40671)
2022 (51850)
2021 (56490)
2020 (55155)
2019 (47966)
2018 (36168)
2017 (32810)
2016 (32289)
2015 (38345)
2014 (31991)
2013 (26987)
2012 (29242)
2011 (29878)
2010 (27875)
Location
Africa (741)
Alabama (53)
Alaska (7)
Arizona (232)
Arkansas (13)
Asia (38754)
Australia (6292)
California (6158)
Canada (2023)
China (528)
Colorado (270)
Connecticut (276)
Delaware (148)
Europe (84514)
Florida (915)
Georgia (216)
Idaho (62)
Illinois (553)
India (26)
Indiana (312)
Iowa (11)
Japan (161)
Kansas (105)
Kentucky (25)
Louisiana (11)
Maine (62)
Maryland (897)
Massachusetts (4617)
Michigan (239)
Minnesota (402)
Mississippi (2)
Missouri (89)
Montana (27)
Nebraska (25)
Nevada (64)
New Hampshire (64)
New Jersey (1743)
New Mexico (29)
New York (1758)
North Carolina (1003)
North Dakota (8)
Northern California (2684)
Ohio (211)
Oklahoma (15)
Oregon (34)
Pennsylvania (1381)
Puerto Rico (12)
Rhode Island (35)
South America (1137)
South Carolina (23)
South Dakota (1)
Southern California (2313)
Tennessee (102)
Texas (916)
United States (23392)
Utah (186)
Virginia (148)
Washington D.C. (64)
Washington State (558)
West Virginia (3)
Wisconsin (63)
712,647 Results for "chf solutions inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Kuros Biosciences grows sales to CHF 75.6 million for 2024
March 11, 2025
·
10 min read
Press Releases
Numab Therapeutics Announces Series C Extension to CHF 180 Million, Completing Oversubscribed CHF 50 Million Financing
January 9, 2025
·
2 min read
Memo Therapeutics increases Series C financing to CHF 45 million
Memo Therapeutics AG announces that it has successfully raised CHF 20 million as part of an extension of its Series C financing, bringing the total amount raised in the funding round to CHF 45 million.
May 7, 2024
·
5 min read
Ikerian AG, Parent Company of RetinAI U.S. Inc. Announces Final Close of USD 6.18M (CHF 5.65M) Series A Extension Financing
Ikerian AG and its subsidiary, RetinAI U.S. Inc. a leading developer of software solutions for medical image and data management
May 2, 2024
·
7 min read
Press Releases
ICU Medical, Inc. and Otsuka Pharmaceutical Factory, Inc. Complete Joint Venture to Bolster IV Solutions Manufacturing and Innovation in North America
May 1, 2025
·
7 min read
Press Releases
Noema Pharma extends Series B financing round, closing at CHF 130 Million ($147 Million)
December 11, 2024
·
3 min read
Santhera Secures up to CHF 69 million in Royalty and Debt Financing to Fund Operations to Cash Flow Break-Even
Santhera Pharmaceuticals announces that it has entered into committed financing arrangements that, when consummated, will provide Santhera with gross funding totaling approximately CHF 69 million to drive growth, repay maturing bonds and extend cash runway through to the first half of 2026, at which point Santhera expects to be cash flow break-even.
June 18, 2024
·
7 min read
Alithea Genomics Closes CHF 2.8 Million in Seed Financing Extension Led by Novalis Biotech
Alithea Genomics, an emerging leader in the field of large-scale RNA sequencing and transcriptomics, announced the closing of a CHF 2.8 million extension to its seed financing.
March 14, 2024
·
4 min read
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
RELIEF THERAPEUTICS Holding SA announced the renewal of its CHF 50 million Share Subscription Facility agreement with GEM Global Yield LLC SCS and GEM Yield Bahamas Limited.
February 28, 2024
·
5 min read
Spineart Secures more than CHF20 Million in Convertible Financing Following Completion of BAGUERA®C IDE Studies Enrollment
Spineart, a global spine specialist working with surgeons to accelerate the adoption of cutting-edge technologies, has successfully raised a CHF20 million convertible financing.
March 18, 2024
·
2 min read
1 of 71,265
Next